Design of potent bivalent thrombin inhibitors based on hirudin sequence : Incorporation of nonsubstrate-type active site inhibitors

Download
  1. (PDF, 1 MB)
  2. Get@NRC: Design of potent bivalent thrombin inhibitors based on hirudin sequence : Incorporation of nonsubstrate-type active site inhibitors (Opens in a new window)
DOIResolve DOI: http://doi.org/10.1021/bi00252a010
AuthorSearch for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for:
TypeArticle
Journal titleBiochemistry
Volume33
Issue48
Pages1444314451; # of pages: 9
Subjectpha
AbstractHirudin from medicinal leech is the most potent and specific thrombin inhibitor from medicinal leech with a Ki value of 2.2 × 10⁻¹⁴ M. It consists of an active site blocking moiety, hirudin¹⁻⁴⁸, a fibrinogen-recognition exo-site binding moiety, hirudin⁵⁵⁻⁶⁵, and a lilnker, hirudin⁴⁹⁻⁵⁴, connecting these inhibitor moieties. Synthetic inhibitors were designed based on the C-terminal portion of hirudin. The bulky active site blocking moiety, hirudin¹⁻⁴⁸, was replaced by small nonsubstrate-type active site ibhibitors of thrombin, e.q., dansyl-Arg-(D-pipecolic acid). The linker moiety was replaced by ω-amino acids of (12-aminododecanoic acid)-(4-aminobutyric acid), and hirudin⁵⁵⁻⁶⁵ was used as a fibrinogen-recognition exo-site binding moiety in most of the inhibitors. The crystal structure of the inhibitor in complex with human α-thrombin showed that dansyl, Arg, and D-pipecolic acid of the active site blocking moiety occupy S3, S1, and S2 subsites of thrombin, respectively, and were therefore designated as P3, P1, and P2 residues. The use of dansyl-Arg-(D-pipecolic acid) improved the affinity (Ki) of the inihibitor 10-100-fold (down to 1.70 × 10⁻¹¹ M) comparted to that of the similar compounds having D-Phe-Pro-Arg as their substrate-type inhibitor moiety (Ki = 10⁻⁹-10⁻¹º M). The linker connected to P2 residue eliminated teh scissle peptide bond. The inhibitor was also stable against human plasma proteases. Further inhibitor design revealed that the toxic dansyl group could be replaced by 4-tert-butylbenzenesulfonyl group and 1- or 2-naphthalenesulfonyl group for in vivo studies. In addition, the replacement of hirudin⁵⁵⁻⁶⁵ with [Tyr⁵⁶,-Pro⁵⁸,Ala⁶³,Cha⁶⁴,D-Glu⁶⁵]hirudin⁵⁵⁻⁶⁵ improved the affinity of the inhibitors (Ki = 2.0 × 10⁻¹³ M).
Publication date
LanguageEnglish
AffiliationNRC Biotechnology Research Institute; National Research Council Canada
Peer reviewedNo
NRC number36847
NPARC number18496956
Export citationExport as RIS
Report a correctionReport a correction
Record identifierd107dd15-6e75-4a48-99cb-04bc482c4b36
Record created2011-08-25
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)